the us food and drug administration on tuesday approved reata pharmaceuticals inc’s treatment for friedreich’s ataxia a rare inherited disease that causes damage to the nervous system reata’s reta stock was halted in afterhours trading on tuesday in advance of the fda’s decision the drug omaveloxolone which is now called skyclarys